Looking for break of pre market high 1.6
PT1 1.78
PT2 2.10
PT3 2.35
Stop at 1.3
"Our proprietary gp96 platform activates the human immune system to combat infectious diseases. Collaborators of Heat Biologics’ have laid a good foundation on engineering different pathogenic antigens into our platform. Previous preclinical studies using gp96 platform includes SIV/HIV, malaria and zika. The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020."
Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform. Such design has the potential of generating long-term immune responses and may confer immunity to different coronaviruses.